Mad Money w/ Jim Cramer · · Transcript & summary by WhipScribe
Jim Cramer breaks down Anthropic's IPO numbers, a CoreWeave interview and a Teva drug-pipeline pitch in one Veterans Day episode.
Tap a chapter to play it from that moment in the show's own player; the transcript opens there too.
“Clearly, Anthropic is doing much better on the profitability front than OpenAI.” Jim Cramer · at 16:55 — ▶ hear it from here
“We go after things where we think there's a high probability of success.” Richard Francis · at 32:58 — ▶ hear it from here
Jim Cramer opens by weighing NVIDIA's leadership troubles against a strong day for chip stocks. He reports that a personnel scandal and backlash against new data centers have made him wary of tech, yet his Investing Club trust kept its NVIDIA position while trimming other data center names. He then describes a morning interview with the CEO of CoreWeave, a heavily indebted cloud company, who said demand for computing exceeds supply, that chips bought four years ago are being re-contracted at 20% to 50% premiums, and that CoreWeave's stock rose 25% that day.
Most of the episode is a Know Your IPO segment on Anthropic, which may price its offering next week at a valuation possibly near $1.5 trillion. Cramer separates the adjusted results from the GAAP ones. Anthropic is profitable on an adjusted operating basis but not yet on GAAP, and the gap is widest at the net income line, where a $104 billion net loss becomes a $5.6 billion adjusted profit mainly because of a $94 billion non-cash charge tied to notes and SAFEs issued to partners. He also notes that the company has committed roughly $900 billion to compute and infrastructure, so its plan depends on rapid, continued growth.
The back half covers restaurant stocks, which rallied as investors rotated out of tech, with a chart analyst favoring Wingstop, Shake Shack and Restaurant Brands International. Other segments include an interview with Teva Pharmaceutical CEO Richard Francis about the drugmaker's schizophrenia and migraine treatments, plus a Veterans Day tribute to FedEx founder Fred Smith, a Marine Corps veteran.
Richard Francis is the CEO of Teva Pharmaceutical, one of the world's largest drug makers. He took over in early 2023 and was interviewed on this episode about the company's first R&D day.
Jim Cramer said NVIDIA's chips bought four years ago are now being re-contracted at higher prices, and that many people once thought the chips would be worthless after one five-year contract. He said the chips have increased in value and that the CoreWeave CEO is making a big bet on the technology.
“When this company started, there were plenty of people who thought these NVIDIA chips would be worthless after one five-year contract.”Jim Cramer · 7:20
Jim Cramer said Anthropic is doing much better on profitability than OpenAI, which he described as still deeply unprofitable with an adjusted operating margin of negative 109 percent. He called that a big reason Anthropic is likely to be the first of the two leading AI labs to reach the market.
“Clearly, Anthropic is doing much better on the profitability front than OpenAI.”Jim Cramer · 16:55
Richard Francis said Teva Pharmaceutical picks research programs where it sees a high probability of success and a deep understanding of the science. He pointed to its long-acting olanzapine for schizophrenia, launched a few weeks earlier, and said the company's innovative medicines could bring in $6 to $7 billion a year by 2030.
“We go after things where we think there's a high probability of success.”Richard Francis · 32:58
Jim Cramer paid tribute to Fred Smith, who started FedEx and led it until 2022, and who died the year before this Veterans Day episode. Cramer said Smith went to Yale, where he studied economics and wrote a paper about starting an overnight delivery business, then served two tours in Vietnam as a Marine.
“Fred went to Yale, where he studied economics and famously wrote a paper about starting an overnight delivery business.”Jim Cramer · 45:09
Richard Francis argued that Teva Pharmaceutical succeeds by choosing drug programs with a high chance of success and by reaching patients with real unmet needs, such as long-acting schizophrenia and migraine treatments. He said Teva's pivot to growth, including its first R&D day, could bring in $6 to $7 billion a year by 2030.
Jim Cramer said reports that NVIDIA CEO Jensen could be out after a personnel scandal, along with backlash against data centers after the midterm vote, made him wary of many tech stocks. He still kept NVIDIA in his Investing Club trust while trimming other data center names, because he judged that holding so much data center exposure was still too risky.
The CoreWeave CEO told Jim Cramer that demand for compute, the end product his company sells from its NVIDIA chips, already exceeds supply and was 10 times oversubscribed for 2027. He said demand for 2028 is also multiples of what CoreWeave can provide, which has let the company raise prices steadily.
Jim Cramer said Anthropic became profitable on an adjusted operating income basis in the second quarter of 2026 and stayed positive in the third quarter. On a GAAP basis it is not yet profitable, though close at the operating line. Through nine months of 2026 its net loss was just over $104 billion, while adjusted net income was $5.6 billion, mainly because of a $94 billion non-cash fair value charge.
Jim Cramer reported that Anthropic's IPO prospectus says it has committed to spend about $900 billion, nearly all of it on compute and infrastructure, with about half due by the end of 2030 and about $70 billion in the next year. He highlighted a $120.5 billion deal with SpaceX running through 2029, with payments above $3 billion per month.
Richard Francis told Jim Cramer that Teva picks research programs where it sees a high probability of success and deep scientific understanding. He pointed to Uzedy, a long-acting olanzapine for schizophrenia launched weeks earlier, and said Teva's first R&D day laid out innovative medicines that could bring in $6 to $7 billion a year by 2030.
Jim Cramer's chart analyst favored Wingstop, Shake Shack and Restaurant Brands International. He saw Wingstop, at $167, rallying 74% from late September lows with a possible run to $200 and then $250. He expected a gap from May to fill at Shake Shack, about 20 to 25% upside, and said Restaurant Brands would need to break above $81 to $82 to confirm a breakout.
On Veterans Day, Jim Cramer paid tribute to Fred Smith, who started FedEx and led it until handing the company to Raj Subramanian in 2022. Smith, a Marine Corps captain who served two tours in Vietnam and received the Silver Star, died the previous year. Cramer also recalled that Smith once turned the company's last $5,000 into $27,000 playing blackjack in Las Vegas.
Our own transcript of the public episode, with a timestamp about every 90 seconds. Tap a timestamp to play the episode from there in the show's own player; the link button on a paragraph copies a link that opens this page there.
0:00Running a business means keeping pace with the latest tech. You've put a lot into building your enterprise software stack, and scrapping it to integrate AI is out of the question. That's why IBM technology works with all the apps, data, and models you need. It's another way IBM helps you build on the technology you rely on. Let's create smarter business. IBM. Visit ibm.com to learn more. worldwide that use Indeed to connect with quality talent that fits their needs. Listeners of this show will get a $75 sponsored job credit to help get your job the premium status it deserves at Indeed.com slash podcast. That's Indeed.com slash podcast. Terms and conditions apply. Hiring now? Then this is a job for Indeed sponsored jobs. My mission is simple, to make you money. I'm here to level the playing field for all
1:07investors. There's always a bone working somewhere, and I promise to help you find it. Mad Money starts now. Hey, I'm Kramer. Welcome to Mad Money. Welcome to Kramerica. Other people, my friends, I'm just trying to save you some money. My job is not just to entertain, but to tell us it is. So call me at 1-800-743-CNBC or tweet me at Jim Cramer. Sometimes you need a reality check, even if you are a huge believer in something. The events at NVIDIA, including the likelihood tonight that CEO Jensen Wang would be out at the company, perhaps as early as tonight, because of another sex scandal, this time with a high-ranking employee, as well as the negative impact to the data center story stemming from the outcome of the big blue wave,
1:57have shaken me, made me gun-shy about a host of tech stocks, many of which have cost investors fortunes. But on a day when the semiconductor stocks shone on a day, while the rest of the average is yawn, Dow climbing 255 points, S&P jumping 1.3%, NASDAQ soaring 1.6%, we got some concrete evidence that you write off this group at your own peril. We want to stay diversified, but giving up on the data center stocks entirely may cause you to miss a good amount of upside. My travel trust, which you can join by going to the CNBC Investing Club, we've taken some data center and related stocks off the table. Unfortunately, not NVIDIA. Because our composure and our prudence dictates that to have so much data center is still too
2:45dicey. I'm not changing that position even after some of these stocks are now above where we sold them. Still, we've left plenty of exposure to the group, which includes semi-self-aware networking, builders, turbines, and cooling equipment because we think the AI theme has much more room to run. But to keep what we call an overweight position in the group these days, you need nerves of tungsten and the confidence of a high-wire walker. That's why I thought an interview we did this very morning on Squawk of the Street with Michael Intrader, the CEO of the leading neocloud core weave, was so refreshing and reassuring, particularly versus the hideous news that seems to be coming out of NVIDIA.
3:24With the big blue wave, a couple of high-profile hedge fund blowups, the weakness in the merger particularly versus the hideous news that seems to be coming out of NVIDIA. With the big blue wave, a couple of high-profile hedge fund blowups, the weakness in the merger market with Marvell Tech and Lumenum, and the heartbreak of an NVIDIA possibly without Jensen Wong, all things considered, I would rather be in Colgate or Johnson & Johnson. The greatest investing story ever told became, almost overnight, a blight on our country, with its chief spokesperson caught up in some tawdry spy scandal that made Theranos look like child's play. With another revelation tonight, Jensen's corner. Unlike print, television interviews tend to live for a few minutes and then die. Most of the time,
4:01they are immediately cremated. But I don't want this one to end up in an urn on top of your TV set. So let me tell you what Intrader said, which might turn you into less of a skeptic as we head into what most likely will be the biggest IPO of all time, Anthropic. While the bankers pitched a $1.3 to $1.4 trillion valuation yesterday morning, by last night there were already rumors it could be increased to $1.5 trillion. Meaning by this time next week we'll be talking maybe $1.6, $1.7 trillion. Seems valid. Seems probably reasonable. We were a little prosecutorial during the interview this morning with Intrader because his company Cori was heavily in debt, in large part because Intrader is such a huge believer in the long-term value of the data center itself.
4:44He's a gigantic buyer of NVIDIA chips, which cost fortunes, so he has to borrow fortunes to do so, fortunes that look to be far in excess of his company's means, at least right now. But the first thing N-Trader did was disabuse us of the value of what he's buying, explaining that demand for compute, that's the end product of what he buys for it, exceeds the supply of it. They already said 10 times oversubscribed for 2027. And he added demand for 2028 is also multiples of what he can provide. What a bullish story. That insatiable demand has allowed him to raise price for services pretty consistently, which expands his gross margins, a terrific barometer of future profits, even if they aren't there today.
5:26He was borrowing money in the open market by issuing bonds, but those bonds have been clobbered to the point where they now offer a 15% yield. Now, that's usually a sign of pending failure. So he's adapted, instead taking down a different kind of debt that has customer prepayments to fund his GPU buying to NVIDIA. His debt problem is no longer front and center. When I pressed him, I asked him, why doesn't he just go into the open market and buy those bonds that are trading so poorly? He admitted that he's tempted because he thinks they're very cheap. But ultimately, he still believes that he can make an even better return building and running data centers. In any case, I think you can take the red flag off the table about that issue.
6:04But how about the big blue wave and the political blowback that now seems to doom the data center in our country? He said it's not going to slow down the building one bit and that if we don't build them here, then we'll simply go overseas where the rules aren't as strict. There is a massive groundswell of demand around the world of computing, he told us. Do you know he wrote an open letter recently to the new governor of Texas, Governor-elect, who seems lukewarm on data centers, explaining the court is what I call a white hat. He says he expects no trouble putting up data centers there. I felt very good after that because there hasn't been much in the way of positive sentiment ever since voters rejected
6:39data centers in 40 of 41 ballot initiatives. Perhaps the most exciting part of the interview, although it was done before a lot more revelations, was when Intrader revealed that NVIDIA chips he installed four years ago will soon be earning much more than when he bought them. The technology he said is coming off contract next year. It has now been recontracted at a 20% to 50% premium to their initial prices. That's right. Starting next year, he'll begin earning more NVIDIA chips that he bought four years ago than he has been for any of the past four years. They have increased in value. Now, keep in mind, when he initially bought these ships, he borrowed on terms that matched his five-year customer contracts.
7:20But beginning next year, Corweave will own them free and clear. So all the revenue that it gets for renting them out is pure profit. Now, that's incredible. When this company started, there were plenty of people who thought these NVIDIA chips would be worthless after one five-year contract. And Trader is making a huge bet on this technology, and it's looking like a good one despite what Jensen Wang is said to be up to, which led somewhat obviously to Jensen, who is now the most pillory person in business. I wanted to know if Jensen were out, what would he think of the company? A pretty prescient question. His response. Look, NVIDIA is an extraordinary company, right? It is not one person. It is an extraordinary company, right? It is not one person.
8:06It is an extraordinary company. There are thousands of people over there that interface with thousands of people at my company every day. They integrate on the technology. They integrate on the physical infrastructure. They integrate on the networking. We have a close relationship with them up and down the companies, and they are a great partner. They have been a great partner for us for years. They will continue to be a great partner for us. Look, I think the chips are obviously going to be worthwhile, but as an NVIDIA shareholder, and that's my trust that owns it, it's definitely not going to be enough. Look, a chest-less NVIDIA is an NVIDIA many will not want to own. I've always said own it, don't trade it.
8:48Well, I didn't think this would happen. I don't know anyone who did. It's very sobering. But Corweave's quarter in this interview with Intrader are why the Nasdaq went higher today. Yes, it was shockingly positive. Corweave's stock itself gained 25% today. Had he been less sanguine and less boisterous, maybe we would not have paid as much attention as we did. But that and the fact that Oracle, a builder of data centers, saw its stock roar after David Faber's interview with the CFO, Hillary Maxson, who talked about that company's success in building data centers, emboldened me. Clearly, others felt the same way based on the action today. Would I still buy some more of these tech stocks right here if Jensen's out?
9:28The only things that are ahead of us that could stop us would be a bad quarter from NVIDIA. I don't think we'll get that, but obviously Jensen not on the quarter is going to shock people. What can you do? And then the Anthropic deal, which should trade next Thursday. Like I said in last night's installment of Know Your IPO series, Anthropic's growth sounds super, but stay tuned for the next leg tonight when we discuss profitability. Here's the bottom line. Today, the markets seem to feel much better about tech and the AI data center. If your portfolio benefited from that, you can thank Michael Intrader. As news reports certainly say, well, then tomorrow's going to be a different story. And I am, yes, heart sick
10:11about it. I thought I knew Jensen. And we leave it at that. Speak to Gary in Alabama. Gary. Hey, Jim. First of all, I want to let you know I was one of your original Investment Club members, and I really appreciate what you and Jeff do for guys like me who don't have time to do the homework. And you do that for me, and I've made a lot of money with you. Thank you, Gary. That's really what we're trying to offer. We're trying to offer institutional research for individuals, but in a way that's far more interesting and understanding. How can I help you? Absolutely. Well, I bought Meta just ahead of earnings, which turned out to be a mistake. And I've made a lot of money off that stock over the years, but I was trying to get back in it.
10:52And that didn't play out well. But I want to know if now is a good time to jump back into that. I like Meta here. Be out. Probably maybe out is what I'm talking. And that could be such a big stock. And you get a chance to buy it cheaper. I would go do it. Let's go to Gus in Georgia, please, Gus. Booyah, Jim. This is Gus in Atlanta. Hey, Gus. Jim, I'm a proud investing club member. And I've had the honor of meeting you and Jensen Wong last fall at your investment club meeting at the New York Stock Exchange. What an incredible experience that was. And Jim, I start and end every day watching you on CNBC. I love your book, How to Make Money in Any Market. You truly changed my life. My family and I thank you.
11:44Thank you. I really appreciate that. Thank you very much. Oh. Thank you. You truly changed my life. My family and I thank you. Thank you. I really appreciate that. Thank you very much. Oh, thank you. So my question is about Jersey Mike's with former Wingstop CEO Charlie Morrison at the helm, aggressive U.S. expansion and international growth beginning in London last week. I love its potential. Jim, the stock's been down, but it's starting to rebound. What's your take? Yeah, it's starting. I think it's an inexpensive stock. But relative to what I think Charlie's going to be able to do, I was not happy. You know, right out of the chute, the first numbers were not what I wanted. But I think they can get better because Charlie's that good.
12:19All right. Typically, I just talk about what's going to be on my money tonight. We're reading the chances out, okay? Now, I got to tell you, I have to scramble. You have to scramble. I feel terrible that I didn't cut that. I didn't cut this one big game. It happens. Actually, no, it doesn't happen. This is incredible. And sometimes incredible things happen. And it's just too bad. We are going to talk about the upcoming Anthropic IPO. We're focusing on one of the more convoluted aspects, profitability. And don't miss my analysis. Then, are the restaurant stocks poised for a comeback amid a tough tape for tech? We'll go off the charts to find out. Heaven Farms and Farmer's Shooter's got some really good stuff.
12:55We're going to sit down with the CEO. And again, am I broken up? Eh, nothing in my life is broken up, but not this one. This one's just disgusting. Stable crime. Don't miss a second of Mad Money. Follow at Jim Kramer on X. Have a question? Tweet Kramer. Hashtag Mad Mentions. Send Jim an email to madmoneyatcnbc.com or give us a call at 1-800-743-CNBC. Miss something? Head to madmoney.cnbc.com. Three ways to pursue outperformance in one active ETF with FYE, the Fidelity Yield Enhanced Equity ETF. FYE can help boost your portfolio with opportunities for not just enhanced income, but also growth and improved after-tax total return, balancing the potential for tax-efficient income generation with exposure to the market's upside.
13:58And it's actively managed by a team of Fidelity experts to adapt to market shifts and seek out performance. Discover FYE, the Fidelity Yield adapt to market shifts and seek out performance. Discover FYE, the Fidelity Yield Enhanced Equity ETF. Learn more at fidelity.com slash FYE. Before investing in any exchange-traded fund, you should consider its investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus and offering circular or, if available, a summary prospectus containing this information. Read it carefully. While active ETFs offer the potential to outperform an index, these products may be more significantly trail an index as compared with passive ETFs. Fidelity Brokerage Services, LLC.
14:30Member NYSE SIPC. Well, here you are again. Your family's annual holiday party. But this year, you bought everyone a gift from Etsy. And is it you, or are the vibes a little different? Like, did your nephew actually just hug you? Yeah, it has my name on it. Your brother's smiling. Hey, this portrait really looks like Banjo. Even Banjo's behaving? You found meaningful holiday gifts for everyone on Etsy? Now it's more than a party. It's a celebration. Until we got AT&T Business Internet, we used to have a guy sleep at the warehouse. His only job was to reset the router overnight when the internet would cut out. If he missed it, we missed orders. One time he operated a forklift while sleepwalking. One should never sleep fork. Now we have AT&T Business Internet. It stays up so Dave can lie down at home.
15:27Thanks, Dave. Thanks, AT&T Business. AT&T Business Internet. Connecting changes everything. This week, we're running a Know Your IPO series on Anthropic ahead of the company's IPO next week. I want you to be fully prepared for what looks like the largest IPO in history. So I'm covering the story from all angles. This time, I talked about the incredible growth that Anthropic has shown, which is the main reason why its valuation has soared. And there's so much interest in this deal. But tonight, I'm going to tackle a more difficult subject. Tonight I'm going to tackle the company's profitability. I want to start with the most positive points. Most notably on an adjusted operating income basis, Anthrop
16:16became profitable for the first time in the second quarter of 2026 and its adjusted operating margin, adjusted operating income divided by revenue, was positive again in the third quarter, even as it fell a bit from the second quarter. Looking at the first nine months of 2026 as a whole, Anthropic is profitable on both an adjusted operating income and adjusted net income basis. To be clear, Anthropic is achieving profitability even on this adjusted operating income basis, is no small matter. Last night, the Wall Street Journal reported some third quarter results for Anthropic's chief rival, OpenAI. And the key takeaways were that OpenAI's revenue growth accelerated in the third quarter. Oh, that's positive.
16:55But it is still deeply unprofitable, with an adjusted operating margin of negative 109 percent. Clearly, Anthropic is doing much better on the profitability front than OpenAI. And that's a big reason why it is going to be the first of the two leading AI labs to make it to market. Now, on a more stringent, generally accepted accounting principles, or you may see that as GAAP basis, Anthropic is not yet profitable. But it's close, at least for the operating income line. So now I want to dig into the adjustments that are being made here, which move Anthropix financial results from the red to the black, as adjusted often does. The good news is that for adjusted operating income metric, there's not actually that much scrubbing being done.
17:38Basically, Anthropix is backing out stock based compensation and non-cash charitable contributions. That's the only difference between its gap operating losses and its adjusted operating income. But wait a second. Is it fair to back out stock-based compensation? That's for you to decide. But I will say that most major software companies do it. In theory, I don't love backing out stock-based compensation. Why? Because compensation seems like a legitimate expense to me. It should be included. But I'm also a pragmatist, and if I decided to die on that hill, I would have missed out on many great growth stocks over the years. Now let's talk about the difference between Anthropic's net loss and adjusted net
18:15income, which is much more substantial. Specifically, again, using that term gap, the gap numbers. Anthropic reported a net loss of just over $104 billion through the first nine months of 2026. But its adjusted net income showed a profit of $5.6 billion. Now, how is that possible? Well, the key swing factor was a $94 billion line item, an expense described as the change in fair value of convertible notes, derivative liabilities, and SAFEs. That's all caps. SAFEs, with SAFEs standing for Simple Agreements for Future Equity. Without getting too bogged down, I know it's hard not to. Here's what this is about. Over the past couple of years, Anthropic has reached wide-ranging agreements with some partners.
18:59Big-name partners, Google, Amazon, that include many different things. For example, Anthropic gets compute resources from these companies and distribution for its models via their cloud platforms. But in exchange, it also is committed to spend billions of dollars with those companies. And to this point, Anthropic also issued convertible notes, essentially debt securities that can be converted into Anthropic equity, as well as other types of securities to Amazon, Google and other partners. But as the value of Anthropic has increased substantially, the value of those securities it issued to its partners, well, they've grown as well. Each time there's a milestone where Anthropic gets a new higher valuation, it has to account for the increase in the value of those
19:38securities at a cost. Crucially, it's a non-cash cost for Anthropic. That matters. But while many investors seem happy to dismiss those huge charges because they're non-cash, I'm not sure they should be ignored entirely. And this brings me to my last most important point. There's one element to the Anthropic IPO prospectus that's a bit of a mystery, and that's the fact that the company has spent very little of the cash that it's raised. Specifically, since its inception, Anthropic has raised approximately $141 billion of capital. But as of the end of September, it had a total of $132 billion in cash, cash equivalents, and short-term investments on its balance sheet. Okay, how is that possible? Especially since the company's not cash flow positive.
20:24It reported its first positive cash flow from operations this year. But even then, it spent much more on investments than it generated from its operating incomes. Right. Operating own operation is a head scratch. But the answer lies, again, in those huge deals with the likes of Google and Amazon. Basically, rather than paying cash for its compute, it's giving stakes in the company to its partners. So while you might dismiss those large non-cash charges as the value of those stocks, instead of the stakes have grown, I might argue that they are a good approximation of what the company would be paying were it to have paid cash for its infrastructure. But here's the more important point. Anthropic has also disclosed in its IPO prospectus that it has made enormous
21:08infrastructure spending commitments for the next several years. I've talked about some of these previously. Remember how I said they'll be paying over $3 billion per month to rent SpaceX compute starting next month? That's part of a $120.5 billion deal with SpaceX that runs through 2029. And that's just one of many such infrastructure agreements that Anthropic has made. It has done this with Google and Amazon, as well as Microsoft and a couple of new clouds, Nscale, Lambda. Anthropic also has reached agreements directly with chipmakers like Broadcom, AMD, for even more compute. All told, Anthropic says in its IPO prospectus that it is committed to spend approximately $900 billion, substantially all of which is related to compute and infrastructure.
21:52About half of that will happen by the end of 2030, and about $70 billion is expected to be spent in the next year. Long story short, Anthropic's compute costs, its cash compute costs, they are going to explode. Now, Anthropic published its IPO Roadshow presentation yesterday. And in that deck, they offer what they call a, quote, long-term financial framework, end quote, which shows how they think this will all work out. Basically, they expect to spend 45 to 50 percent of their revenue on compute and infrastructure, plus another 7 to 10 percent on revenue apiece on sales and marketing and all other costs, including personnel. It all works out, they say, to a roughly 35 percent adjusted operating margin in the long run. Well, that's
22:36all well and good. But with the numbers for compute commitments and the fact that Anthropic expects that spending to amount to less than half of revenue in any given year. You've got to assume that this company is going to continually continue growing substantially to the point where it has hundreds of billions of dollars in revenue per year. And soon that's the only way this work. But it might work. And that really is the bottom line here. When it comes to Anthropic's profitability, yes, the company has achieved profitability. But only if you strip out some key costs that some would say, including me, shouldn't be stripped out. But the more salient point is that Anthropic is due to spend an enormous
23:12amount in the future. So it needs to continue growing rapidly to outrun those costs and remain profitable. That's the bet you're making if you buy the Anthropic IPO. And just to tell you, after all this, I call me intrigued because it is one fast-growing company and I care about growth. Their money is back after the break. Coming up, Kramer's going off the charts to see which restaurant stocks are best positioned to succeed in the current rotation. Next. With my Sapphire Preferred card, we took a trip. To a desert oasis. Earning five times the points on Chase Travel, two times the points on all other travel, plus $100 hotel credit. Chase Sapphire Preferred, a card that's preferred for a reason.
23:57Cards issued by JPMorgan Chase Bank and a member of FDIC. Subject to credit approval. Terms apply. How did I get here? I've spent 20 years building motorcycles. I've been building something for my family too. Invest in where you're going. Get the growth potential of mid-cap companies in one ETF with MDY from State Street. Before investing, consider the funds, investment objectives, risks, charges, and expenses. Visit statestreet.com slash IM for a prospectus containing this and other information. Read it carefully. MDY is subject to risks similar to those of stocks. All ETFs are subject to risk, including possible loss of principal. Helps distributors and distributor. Your team is on a deadline, but moving all your enterprise data will take time
24:36your business simply doesn't have. IBM technology lets AI work with your data where it already lives with an open hybrid cloud approach designed to build on your existing investments. It's another way IBM helps you put your data to work. Let's create smarter business. IBM. Visit IBM.com to learn more. For the past several weeks, as investors have rotated out of tech stocks and the AI trade, many have moved into other groups that previously have been struggling, including many consumer discretionary sectors like the restaurant stocks. When gas prices and interest rates spiked in the back half of the summer, investors left most of the consumer discretionary stocks, as they're called, for dead,
25:29thinking that squeezed consumer budgets would result in weak spending and make for a tougher operating environment for retailers and restaurants, as it always has. But that assumption turned out to be wrong. We had sequentially positive retail and food services sales growth in both August and September. And it was the food services category doing a lot of the heavy lifting those months. Really kind of extraordinary. Once investors started fleeing tech last month, many restaurant stocks started to rally hard. In just the past few weeks, we've covered several of them, including Chipotle, which you know we called the bottom one. Brinker, Eat, we like that. McDonald's, we say it's good. Texas Royals and Starbucks. Now the latter has turned into a big win
26:03for my travel trust, which of course you can follow by joining the CBC Investing Club to help find some more restaurant stocks that are working in this group. We reached out to Bob Lang, old friend, founder of ExplosiveOptions.net and the author of Know Your Options, who said he sees more upside in three fast food stocks. He likes Wingstop. He likes Shake Shack and he likes Restaurant Brands International. All three of these companies have delivered strong earnings results in recent weeks. Lang says that they've been able to take price without hurting demand. Highly unusual in this environment. And with relatively low comps from earlier this year, he thinks this could be a sleeper group that's primed to do well into next year as well. But most of all, he
26:43likes what he sees from these charts. We're going to start with one that I haven't been a big fan of at all since it blew up a long time ago. It's called Wingstop, which this one he calls his favorite name in the group. Wing shares have been under pressure for most of the year, but they've had a massive rally, climbing 74% from their late September lows. This is a really nice move. The rally's come with good volume trends recently, Lang says, and the stock broke out above some important medium term resistance levels in mid-October. Here at the bottom, which we're looking at, it's the MACD, moving average convergence divergence line. This indicator, which technicians use to measure momentum strength, is now firmly on a
27:22buy signal. You can see that really well. At the top, the RSI, or relative strength index, the wing stop shows a stock is in overbought territory. But Lange says there's no reason to be a seller. Sometimes it's just an incredible show of strength. OK, now he likes that the stock recently retested the 200 day moving average in red and held. That level has gone from resistant to support. Overall, he thinks the recent pattern of higher highs and higher lows for wing shares is a textbook bullish setup. He could see this $167 stock make a run first to $200 and eventually to $250. This would shock me, and I don't care for the stock, but I am a huge fan of Bob Lange's work. Next, let's take a look at the chart of Shake Shack, which gapped down after a bad earnings
28:08miss in May and has spent most of the past six months in the penalty box. But Lang thinks that the huge gap lower on high volume got some weak hands out of the stock. Look at that, huh? And then you got this real long base that Shack has had just what the bulls need. At this point, many investors are skeptical about buying the stock. But Lang says that makes it a perfect time to be getting long. He noted the stock's breakout above the 200-day moving average. Now, the 200-day is in red here. You've got, we're starting to really see some, this is a fabulous sign, a powerful move. Here at the bottom, Lang points out that the MACD recently made a bullish crossover as well, though he does note that the RSI up here at the top of the chart shows the stock is approaching
28:51overbought territory. But he also says that the options flow look good for Shake Shack with a lot of interest in the call options at the $75 and $80 strike expiring later this year and into the first half of 2027. Bob always looks at that stuff. I always feel I respected his work like that. Overall, Lang thinks the gap from May will be filled within the next few weeks. And if he's right, that means about 20 points or maybe 25 percent upside for Shake Shack, a stock that is expensive. And again, I've been cautious on. I'm growing less cautious when I listen to Bob. The last stock that Lang likes is restaurant brands, QSR, parent company of Burger King, Popeyes, Tim Hortons, and the smaller firehouse subs. This
29:31stock has been range bound for months with a fairly wide range on moderate volume. Lang says that means the big money is trying to figure out this one. Each time it moves into the 80s, and you can see this, this very interesting pattern, it gets knocked back down. Bulls and bears alike are getting frustrated with this stock. Sure, they are bounce, bounce, you know, knock down, knock down. Could it happen again? But QSR's strong start to this month has caught Lang's attention. The MACD here at the bottom has flipped to a strong buy signal. This is that flip right here. OK, and the average, it's all starting to turn as well. The RSI at the top of the chart shows there's still some room before this one gets too overbought.
30:11He likes that. Lang points out that the volume trends here are becoming more bullish as well. You see the volume getting a little bit higher. Overall, Lang wants to watch QSR shares closely as they re-approach the low 80s, a level that has represented resistance a couple of times already this year. But if restaurant buyers can break out above the key $81 to $82 level, that would be extremely bullish. Lang says a move through that level would confirm a breakout, and the stock could easily make it to the triple digits. Here's the bottom line. The charges interpreted by Bob Lang show that the restaurant stocks have made an excellent move higher in recent weeks. But Lang thinks there's still more upside for some of them. He likes Wingstop
30:48best, thinks Shake Shack is looking good, and restaurant brands, well, he's approaching, he says he's approaching a major test as they move back toward previous highs. Now, if the stock passes that test, then he thinks there's an awful lot of room to run. Chris in Louisiana. Chris. Hey, Jim. All right. What's happening? Can we talk steaks? Yeah, why not? Darden restaurants, Jim, should I saddle up or should I saddle out? I think that, look, I think Darden is absolutely terrific. They offer great value at Olive Garden. I think you should continue to buy the stock. Even though it's on the spike, I think it does go higher. All right. There's much more mad money ahead, including my exclusive with Teva Pharmaceutical. Then this Veterans Day, I'm shining a light
31:31on one fantastic executive whose military service influenced his career and the company itself. And of course, all your calls rapid fire tonight's edition of The Lighting Round. So stay with Kramer. Recently, Teva Pharmaceutical, one of the world's largest drug makers, released some solid earnings to beat on both the top and bottom lines and a raise of its full year sales forecast. Under Richard Francis, who took over in early 2023, Teva's put more money behind its own branded drugs and its transformation from a pure play generics company to a biopharma. This was a $9 stock when Francis took the job. It's now above $43. Today, its first ever R&D day, Teva laid out how its innovative medicines could
32:19bring in $6 to $7 billion a year by 2030. Can the next wave of drugs keep this stock running? Let's check in with Richard Francis, Teva's president and CEO. Richard Francis, welcome back to Mad Money. Thanks, Jim. Pleasure to be here. I tell you, Richard, I had to stop myself when I was thinking about this because there would have been no reason to have an R&D day before you. Yeah, no, it's true. Actually, when I presented today, my first thing I said on the stage was, this is Teva's first ever R&D day. I remember speaking with previous Teva CEOs, and they wanted to come on the show. And I always say no, because it would always be, I felt an embarrassing thing. Well, what have you stolen here? What have you,
32:58what copyright have you broken there? You are breaking ground in some things that when I saw you in January, I actually was critical of, because I didn't think you could do it. And you have succeeded on migraine, on tardive dyskinesia. You're doing some incredible things in schizophrenia. I don't even know where to begin. These are all things I feel that companies won't tarry. As I mentioned in January, they don't go after because what happens is at their analyst day, they have to say, I'm sorry, we struck out. What are you doing right that the other guys can't do? Well, I think what we actually outlined today in our R&D strategy is we're sort of pragmatic. We go after things where we think there's a high probability of success.
33:37We really understand the science deeply. And then we think, OK, we can we can make something successful. And a good example of this is Welltrusa, a long-acting olanzapine that we launched just a few weeks ago. Now, olanzapine as a molecule is regarded as the most efficacious treatment for schizophrenia. The challenge has been no one's been able to make a long-acting injectable. Now, obviously, compliance and adherence for schizophrenia patients who suffer from severe schizophrenia is really important. You don't have to do it at the doctor's office? You don't have to monitor it? No, there's no monitoring for our well-trues. So we thought, okay, how do we crack this long-acting? So we spent a lot of time working
34:14on that. But so one could say that we knew the molecule worked, we just had to make it long-acting and once monthly. And when we did that and we launched it, the reception we received from the psychiatric community and the patients has been really, really positive because that's the unmet medical need. So I think what we do really well is we go after real patients' unmet medical need, focus where we have real capability, whether that's drug delivery or whether that's innovative mechanisms. And then we really prosecute it aggressively and we move fast. Well, I would point out that I have been with another drug company that recently failed on schizophrenia. And they told me that the reason why is because it's just too hard. There's really
34:49no hope. So obviously they should attend to your meeting. Maybe they would have found that out. No, it is hard. It is hard. Okay. So let's talk about bipolar because bipolar is another one that a lot of drug companies have kind of said, well, let's just leave it to Lamictal. Let's leave it to a 1950s anti-seizure drug. Why are you not content with the 1950s anti-seizure drug as a way to be able to treat bipolar? Well, I think what we noticed when we launched Yosedi, our long-acting treatment for espiridone, so we now have Yosedi, which is long-acting, and Olanzapine, the long-acting. So we really have, I think, an ability to help about 85% of patients who suffer from schizophrenia with well-known molecules. When it came to Yosetti, we expanded that indication into bipolar about 12 to 18 months
35:30ago. And obviously, you know, that's the potential we can do with the same with Olanzapine. But what is interesting, Jim, is we've just bought an asset from a company, BioXcel, which will treat agitation for schizophrenia and bipolar at home. So that's another area where patients really don't have treatment because obviously agitation with bipolar and schizophrenia is very common. Roughly about two to three million people have that symptom, but they can't be treated at home. So they have to go into hospital, into a clinic. So it's just another area where we're treating both schizophrenia and bipolar, building out on our schizophrenia franchise to a real scale. And Adobe, how is that different from Newark Tech or Amavik?
36:11So Adobe is a great story. So when we start on the pivot to growth, no one was talking about Adobe. People thought it had its day. It was $400 million. This year, we're going to do over $900 million. We've got peak sales of over a billion dollars. The reason why it's doing so well is because... And this is for migraine, I'm sorry. This is for migraine. A long-acting treatment for migraine is an injectable CGRP. And the reason why it's done really well is, firstly, it's a great product profile. It's very efficacious. It's convenient for the patient. But I think this goes back to our commercial capability at Teva as well. We really understand the patient journey, whether it's in the United States, whether
36:43it's in Europe or other markets. We have grown our market share consecutively. Even though it is, is it a copycat CGR? No, no. This is an innovative product we brought to the market many years ago. But I think in our hands, what we've shown under the pivot to growth, we invested more, we understood more, and we did the pediatric indication. Often forgotten. You launch a drug and then you don't do the pediatric. Sorry, good point. There is no pediatric for the ones I'm talking about. Finally, 2027, what do you have? 2027, it's going to be a pretty busy year. So obviously we launched Welltruse at the end of this year. We'll have that for the first year next year. We'll launch Ecopipan, a treatment for Tourette's syndrome. So that's a deal we did last year.
37:20Another one that people say you can't be cured. Exactly. So I'm super excited about as a father of three, just the idea that we can help children in their formative years in a very difficult condition. And then obviously we hope to be launching the treatment that we got from the asset that we bought out of Bios Excel. And then just keep driving a Jovi, Yosedi, Waltruza and Esteto, a treatment for tardive dyskinesia, which was up 30 percent in quarter three. So we have those. And then we have one launch every five years for the next five years. And then we have a launch probably every 18 months. Well, you should be very proud of what you're doing. I do a lot of work with the brain because of problems with the brain.
37:56I don't mind saying that. People are not supposed to talk about it. That's why brain doesn't get solved because no one talks about it. I do. The American Brain Foundation, the stuff you're tackling is incredible. And I thank you. I thank you for talking about it. Absolutely. Thank you for having us on the show. Of course. That's Richard Francis, CEO of Teva Pharmaceutical. The old Teva I wouldn't put on. This Teva I take. You have my respect after the break. Coming up, he's the fastest mind on Wall Street. So we're putting him to the test with your help. Bring on the lightning round next. It is time. It's time for the lightning round. Chris, I'm going to start. I'm going to start. I'm going to Chris, I'm going to start with Ronald in Florida.
38:54Ronald. James, Ronald from Wellington, Florida. Alibaba. I think Alibaba is the only Chinese stock that I would possibly buy. It's not my favorite right now because the consumer is so weak in China, but it is the only one that I would buy because it's got American financials. Let's go to Roy in New Jersey. Roy. Hey, Jim, boy, it's a great pleasure for me to be talking to you. You're very kind. What's going on? The ticker I have is TGP. Triclor metals. Speculative copper stock. Speculative copper stock with a lot of copper stock. The copper is still being used in the data center because they haven't converted it to fiber yet. I think you can catch a good one. Let's go. But it's back. Robert in Florida.
39:37Robert. Hello, Jim. Robert. Robert in beautiful Tampa, Florida. Thanks for taking my question. My pleasure. I'm long draft kings at about 25, and as you know, they got hammered after the quarter three earnings. I'm concerned about their customer acquisition costs and competition from companies like Cowsheet. I learned, though, that after the earnings— I think you're right. I think you're right to be concerned. There's way too much competition. I don't know. It's withering competition. Everybody's a loser. And I think there's too much gambling in the country. That's my own personal view. But it's also been the view starting to be the prevailing view at the investment houses of this country. I no longer
40:19can possibly recommend any of these gambling stocks because they're all one thing. Gamble. Let's go to Bill in Texas. Bill. Booyah, Jim. Booyah. Proud club member here and a long-time listener. You're still the best. Thank you, man. Thank you. Thank you very much. Thank you. How can I help? I want to get your thoughts on one of my favorites. Origin Bank Carp, symbol OBK. You know, I've got to tell you, How can I help? I want to get your thoughts on one of my favorites, Origin Bank Cards, symbol OBK. You know, I've got to tell you, I've actually made a lot of money buying Louisiana banks over the multiple years because there's a lot of consolidation in them. This is an inexpensive bank stock, not that good a yield, but I like it.
40:57I think you've got a good one, and I actually would encourage you to buy it. Let's go to John in New Jersey. John. Oh, yeah, Jim. Oh, yeah. It's John from Ag Harbor Township. What's your opinion on Palantir? My dad did a lot of business in Ag Harbor. There were like three retail stores he sold bags to. I think that Palantir stock is worth $200 and Fry's isn't there yet. They did have an excellent quarter. Alex Karp is doing a terrific job. Let's go to Hank in Indiana. Hank. Yes. Hello, Mr. Kramer. Hey, Hank, what's up? Thanks for taking my call. I'll get right to the point. I'm in my mid-70s. My grandson's 10 years old. We both own shares in energy transfer. I bought the shares for potential growth
41:43and it's dividends. I got two questions. For my shares, should I buy more, hold or sell? For my grandson, should I buy more, hold or sell and reinvest? Okay, for you, I want you to buy more. I think it's shorter for your grandson. It's not risky enough. Believe it or not, what you have to do is you have to buy something that has more growth to it. But nothing crazy. I mean, I'm talking about a J&J. I'm talking about a Procter & Gamble. I would do that because you do not need to worry. He's got his whole life ahead of him. I say don't do that. Buy something more aggressive. Let's go to Spars in California. Spars. Red, white, and blue. 250 years of American exceptionalism. Veterans Day. Booyah.
42:28Booyah is right. And thank you. Thank you, everyone, for serving. All right. Dr. J., we're looking at Netscope and TSK. You know, it's just one more cloud security platform. You know, we like CloudStrike and we like Palo Alto Networks and we don't need any more beyond that. And that, ladies and gentlemen, is the conclusion of the Lightning Round. The Lightning Round is sponsored by Charles Schwab. Coming up on this Veterans Day, Kramer is paying tribute to all those who served. Next. Tomorrow, kick off the trading day with Squawk on the Street. Live from Post 9 at the NYSE. I am sorry. I wish I had made it up. You know, it would have been better if I had said, David, I have an idea, instead of what the truth is.
43:29But I'm stuck with the damn truth. Which you, by the way, cannot handle. I can't handle it. It all starts at 9 a.m. Eastern. Jim Kramer, the diehard of the dollar. Hey, Jimmy, love the show. My five-year-old grandson loves to watch your show. I have to thank you for making us money when it's there to be made. Our world is a better place with you in it. We cannot go a whole show without saluting the men and women who serve and have served in our military on this November 11th, known since President Eisenhower as Veterans Day. It's a day where I find myself grasping at the greatness of those who serve who willingly put themselves in harm's way. Like the great Marine colonel I write about at the beginning of How to Make Money in Any Market, a quiet hero who inspired me to start
44:33investing after he showed me how he started buying Merck as soon as he got back from the war. Built a small fortune. My dad served, too, in the Army. He won a battlefield commission, promoted in the midst of a battle when all above his rank were incapacitated or killed in the Battle of Lady Gulf in the Philippines. I didn't know what that meant. I didn't know what my hero, my father, was until he passed away. He was a simple soldier who signed up after Pearl Harbor and served in the Pacific. I didn't know he had done something heroic, though, until I went to an NFL football game with a man I revered for years and years, Fred Smith, who started FedEx and built it into the colossus that it is today before turning it
45:09over to Raj Subramanian in 2022. Fred died last year, and I wish his passing had gotten more attention given the fabulous career he led and how much he did for veterans while he built FedEx. Fred went to Yale, where he studied economics and famously wrote a paper about starting an overnight delivery business. But she got either a C or a D one. Fred had forgotten the grade, but he remembered it was a bad one. After graduating, he then signed up for the Marine Corps to serve in Vietnam. Several times, Fred marveled to me about the old days when you just when you just did that because it was the right thing to do. He did two tours and retired as a captain. He received the Silver Star for gallantry in battle. His citation is too long to list,
45:52other than to say that he risked his life for his soldiers repeatedly in a battle against the North Vietnamese. In his first tour, he was a grunt, but in his second, he served as a forward air controller, guiding bombing strikes. When I saw him last, he took out grunt. But in his second, he served as a forward air controller, guiding bombing strikes. When I saw him last, he took out a black and white picture of his platoon and told me how many of the men I was looking at were killed in the war. He pointed to each one. It was a somber moment, simply something Fred wanted me to see. He was determined to let me know of these soldiers, to remember them. And I do that this day. I took some gambles literally when FedEx was in its infancy.
46:27At one point after being denied a loan, he took the company's last $5,000, flew to Las Vegas and turned it into $27,000 playing blackjack, saving the company in the process. He laughed about it when he told me the story. I asked him to tell it to me a couple of times. I liked it so much. His service in the military helped guide him through all the years and reversals of his fortune. His successor, Raj, told me today that FedEx culture was built on people first principles that Smith learned in the military. Our culture is our bedrock, Raj said. Lots of initial FedEx employees and pilots were from the military and still are from the military. Fred liked the American Battlefield Monuments Foundation,
47:05which maintains the beautiful cemeteries of Americans who died overseas. He had mentioned my dad in conjunction with that. He said he told me my dad was a hero. And that's where I learned of it. I give to the foundation for my travel trust. I do it in honor of Fred. I know Fred will always be known as the person who started the amazingly successful FedEx or the exec who opined most eloquently about the economy at the beginning of a bunch of TV shows I did. But when I spent time with him, he just wanted to talk about the importance of his time in the military and those who serves so their deaths and struggles were not in vain. He was quite the man, quite the veteran. Fred, on this day, we salute you and the millions of others who have served,
47:46along with the men who served with you in Vietnam, who never returned. I like to say there's always a bull market somewhere, and I promise to try to find it just for you right here on May It Money. I'm Jim Cramer. See you tomorrow. All opinions expressed by Jim Cramer on this podcast are solely Cramer's opinions and do not reflect the opinions of CNBC or its parent company or affiliates and may have been previously disseminated by Cramer on television, radio, internet, or another medium. You should not treat any opinion expressed by Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Cramer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy,
48:27and it should not be relied upon as such. To view the full Mad Money Disclaimer, please visit cnbc.com forward slash madmoneydisclaimer. Hey, it's Parker Posey. How did I get here? I love improvisation when it comes to acting, but when it comes to a real-life plan, I stick to a script. Cue the music. Invest in your story with DIA, the only ETF that tracks the Dow. From State Street, getting there starts here. Before investing, consider the fund's investment objectives, risks, charges, and expenses. Visit statestreet.com slash IM for perspectives containing this and other information. Read it carefully. DIA is subject to risks similar to those of stocks. All ETFs are subject to risk, including possible loss of principal.
49:02Alps Distributors, Inc. Distributor.

